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ABSTRACT 
 
Single nucleotide variation in C13orf31 encoding p.C284R and p.I254V in a 
protein of unknown function causes systemic juvenile idiopathic arthritis, and 
associates with risk for leprosy and Crohn’s disease, respectively. Here we set 
out to uncover the underlying mechanism. C13orf31 formed a complex with fatty 
acid synthase on peroxisomes and promoted flux through de novo lipogenesis to 
concomitantly drive high levels of fatty acid oxidation (FAO) and glycolysis, and 
consequently ATP regeneration. C13orf31-dependent FAO controlled 
inflammasome activation, mitochondrial and NADPH oxidase-dependent 
reactive oxygen species production, and bactericidal activity of macrophages. 
With p.I254V and p.C284R exhibiting decreased and loss of function, 
respectively, C13orf31 determined organismal resilience to endotoxin shock. We 
hence discovered a central regulator of macrophage metabolic function and 
bioenergetic state, which is under evolutionary selection and determines risk for 
inflammatory and infectious disease. [134/150] 
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Immune-related diseases arise from complex environment – gene interaction. While 
the external triggers remain enigmatic, human genetic studies have revealed the 
genomic risk landscapes of these conditions. Genes encoding proteins with immune 
function were predictably identified as plausible candidates at various risk loci. The 
mechanistic contribution of their polymorphic variants to disease pathophysiology has 
been experimentally addressed for a few of these genes, though remains largely based 
on conjecture for most. Furthermore, for a large number of risk loci and –genes it 
remains entirely unclear how they are mechanistically involved in disease, including 
some, for which no biological function is known yet at all. We hypothesized that the 
latter may single out novel mechanisms that are not only important for human health, 
but for mammalian biology in general. 
 
Two coding polymorphisms in C13orf31 (also known as LACC1), an open reading 
frame encoding a protein of unknown function, rendered this gene and its product 
particularly intriguing: firstly, homoallelic carriage of a rare missense mutation at 
g.43,883,879T>C, leading to p.C284R, has been linked in consanguineous families to 
systemic juvenile idiopathic arthritis (sJIA), a periodic fever syndrome, and to early-
onset Crohn’s disease (EOCD), an inflammatory bowel disease1, 2. Secondly, the 
haplotype identified by the common rs3764147 (g.43,883,789A>G) single nucleotide 
polymorphism (SNP), leading to p.I254V, has been associated with increased risk for 
leprosy, an infection caused by Mycobacterium leprae, and Crohn’s disease (CD)3, 4. 
 
Here we report that the protein encoded by C13orf31 serves as rheostat for the 
synthesis of endogenous fatty acids and their mitochondrial oxidation, thereby 
controlling glycolytic activity and overall ATP regeneration. As a consequence, this 
polymorphic gene determined mitochondrial and NADPH oxidase-dependent reactive 
oxygen species (ROS) production, bactericidal activity and inflammasome activation 
in macrophages, prompting us to name this protein FAMIN, fatty acid metabolic – 
immune nexus. 
 
RESULTS 
FAMIN interacts with fatty acid synthase 
C13orf31 mRNA is most highly expressed in macrophages and predicted to encode a 
cytoplasmic protein of 430 amino acids (aa) that lacks similarity to other mammalian 
Page 4 	
protein families5, 6. We performed an unbiased proteomic search for interaction 
partners to begin unravelling FAMIN function. After discounting proteins involved in 
protein synthesis, folding, degradation and cytoskeletal organization, fatty acid 
synthase (FASN, EC 2.3.1.85) was the top peptide hit detected with N- and C-
terminally Strep-tagged FAMIN expressed as bait in HEK293T cells 
(Supplementary Fig. 1 and Supplementary Table 1). Endogenous FAMIN 
reciprocally co-immunoprecipitated with FASN in lysates of primary human 
monocytes differentiated into macrophages, as well as in lysates from human THP1 
and U937 monocytic cell lines differentiated into macrophages (Fig. 1a). Proximity-
ligation assays (PLA) further confirmed co-localization of FAMIN and FASN in situ 
(Fig. 1b). The two common polymorphic variants FAMIN.p254I and FAMIN.p254V 
exhibited equivalent interaction with FASN in coimmunoprecipitation experiments 
using HEK293T transfectant lysates (Fig. 1c), further corroborating that FAMIN is in 
a complex with FASN. 
 
Mammalian FASN is a large cytoplasmic polypeptide multi-enzyme central to de 
novo lipogenesis (DNL)7. FASN associates with membranes at different subcellular 
compartments8. We therefore performed confocal microscopy to determine the 
intracellular localization of FAMIN in macrophages differentiated from primary 
human monocytes and THP1 cells. FAMIN immunofluorescence (IF) revealed near-
perfect co-localization with peroxisome-markers 70-kDa peroxisomal membrane 
protein (PMP70; encoded by ABCD3) and catalase (Fig. 1d and Supplementary Fig. 
2a–c ), while little co-localization was present with other organelle markers 
(Supplementary Fig. 2d,e). Co-localization between FAMIN and PMP70 was 
confirmed by PLA (Fig. 1e and Supplementary Fig. 2f), corroborating the 
peroxisomal localization of FAMIN.  
 
Peroxisomes are organelles involved in lipid metabolism, which closely associate 
with lipid droplets and mitochondria9. Macrophages exhibit metabolic and functional 
plasticity, epitomized in vitro by culture under non-polarizing (M0), ‘classical’ (M1), 
and ‘alternative’ (M2) activation conditions10. While aerobic glycolysis is a defining 
characteristic of ‘inflammatory’ M1 macrophages and their primary mechanism for 
ATP generation11, ‘regenerative’ M2 macrophages rely on mitochondrial fatty acid 
oxidation (FAO, also termed b-oxidation) to fuel oxidative phosphorylation 
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(OXPHOS)12. To study FAMIN function, we generated mice with knock-out alleles 
of 9030625A04Rik (also known as Lacc1), the murine homologue of C13orf31, which 
we will refer to as ‘mFamin’ (Supplementary Fig. 3)13. Similar to FAMIN, FASN 
does not contain a peroxisomal localization motif, and has previously been shown to 
complex with PMP70 on the cytoplasmic side of peroxisomes9, 14. Consistent with 
this, we found that a proportion of cellular FASN immunoreactivity, 20±3% and 
4±2%, co-localized with catalase+ peroxisomes in wild-type M1 and M2 
macrophages, respectively, and this was not affected by absence of FAMIN (Fig. 
1f,g). PLA confirmed these spatial relationships (Fig. 1h,i). Bone marrow-derived 
macrophages cultured under M0, M1 and M2 conditions all expressed mFamin 
mRNA, with highest levels observed when differentiated under M1 conditions 
(Supplementary Fig. 4a). Fasn mRNA expression was similar in mFamin+/+ and 
mFamin–/– macrophages, with highest expression observed under M2 conditions 
(Supplementary Fig. 4b). In addition, FASN protein expression was also equivalent 
in mFamin+/+ and mFamin–/– M1 and M2 macrophages (Supplementary Fig. 4c). 
Together, our data indicate that FAMIN and FASN form a complex on peroxisomes, 
and peroxisomal FASN localization, which is particularly prominent in M1 
macrophages, is not impaired in mFamin–/– cells. 
 
FAMIN controls carbon flux through DNL 
FASN catalyzes all steps of long-chain saturated fatty acid (LCFA) synthesis 
(predominantly C16:0 palmitic acid)15. This enzymatic reaction utilizes cytoplasmic 
acetyl-coenzyme A (CoA), malonyl-CoA (generated from acetyl-CoA by 
carboxylation), and nicotinamide adenine dinucleotide phosphate (NADPH)15. 
Cytoplasmic acetyl-CoA is itself generated by ATP citrate lyase (ACLY) following 
the export of mitochondrial citrate formed during glucose- or amino acid-fuelled 
Krebs cycle activity16. In consequence, FASN function allows storage of excess 
energy, derived from glucose and amino acid oxidation, in lipid droplets upon LCFA 
CoA-activation and –esterification to triacylglycerols (TAGs)17. FASN also 
synthesizes fatty acyl moieties of membrane lipids and provides the precursors of 
many other cellular and signaling lipids. In view of the diverse functions of lipid 
moieties dependent on FASN function, the precise channeling of its products into 
distinct metabolic pathways is essential15, 17.  
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To assess FASN activity in situ, we pulse labeled murine bone marrow-derived 
macrophages with [13C1,2]-glucose (Supplementary Fig. 5a). Uptake of 13C into total 
LCFA and C16:0 was below the detection limit (data not shown) in both mFamin+/+ 
and mFamin–/– M1 and M2 macrophages, consistent with limited turnover and 
exogenous uptake of the large pools of free fatty acids. However, we did observe 13C 
incorporation into C16:0 and C18:1 fatty acyl CoA esters, the activated forms of 
LCFA utilized for lipid synthesis and mitochondrial oxidation, in wild-type M1 and 
M2 macrophages (Fig. 2a–d). Together, these data imply that newly synthesized fatty 
acids are immediately CoA-esterified for subsequent use and thus do not determine 
the abundance of the free fatty acid pool. Furthermore, we discovered that 
incorporation of 13C into C18:1-CoA in M1 macrophages and C16:0-CoA and C18:1-
CoA in M2 macrophages were profoundly reduced in mFamin–/– compared to 
mFamin+/+ MΦ (Fig. 2a–d). Total LCFA-CoA abundance was also significantly 
reduced in mFamin–/– compared to mFamin+/+ M1 and M2 macrophages (Fig. 2e,f), 
while total fatty acid content, including C16:0, was predictably indistinguishable 
between genotypes (Supplementary table 2). Together, these data indicate that 
FAMIN determines, via DNL, the fatty acyl CoA availability for processes such as 
FAO.  
 
FAO requires transport of CoA-activated LCFA across mitochondrial membranes as 
acyl-carnitine esters18. The exchange of CoA for carnitine by cytoplasmic carnitine 
palmitoyltransferase (CPT1a) is the rate-limiting step of FAO18. Consistent with a 
reduction in the specific availability of fatty acyl-CoA, incorporation of 
[13C1,2]glucose-derived 13C into fatty acyl carnitine species (total acyl-Cn and C16:0-
Cn) was markedly lower in mFamin–/– compared to mFamin+/+ M2 macrophages (Fig. 
2g,h), while incorporation was below the detection limit in M1 macrophages (data not 
shown). Importantly, while incorporation of glucose-derived 13C into acyl-CoA was 
substantial after a 24 h pulse (~20-30% of C16:0- and C18:1-CoA in wild-type M2 
macrophages), it was low for acyl-Cn species (~4% of total acyl-Cn in wild-type M2 
macrophages) at the same time point. Altogether, FAMIN directly controls the flux of 
glucose-derived carbon into DNL and onwards into acyl-Cn, the latter possibly 
involving an intermediary step via TAGs12. 
  
FAMIN controls glycolysis via DNL  
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To determine whether loss of FAMIN consequently influenced glycolytic metabolism 
in macrophages, we measured the extracellular acidification rate (ECAR), an 
indicator of glycolysis19, in wild-type and mutant macrophages. We found ECAR was 
profoundly reduced in mFamin–/– compared to mFamin+/+ M1 macrophages, with a 
similar proportional decrease from an expectedly lower baseline observed in M0 and 
M2 macrophages (Fig. 2i–k). The differential in ECAR was further increased upon 
blockade of the F0 subunit of mitochondrial ATP synthase with oligomycin A (Fig. 
2i–k), which stimulates alternative ATP generation via glycolysis20. This observation 
implies that FAMIN-dependent glycolysis is maximized under conditions where 
mitochondrial respiration is uncoupled from ATP synthesis. ECAR was abrogated in 
mFamin–/– and mFamin+/+ macrophages alike upon inhibition of glycolysis with 2-
deoxy-D-glucose (Fig. 2i–k). Similarly, ECAR measurements performed in the 
presence of exogenous pyruvate, hence bypassing glycolysis, were indistinguishable 
between mFamin–/– and mFamin+/+ macrophages (Supplementary Fig. 5b). 
Altogether, these data demonstrate that FAMIN determines the baseline and 
maximum glycolytic capacity of macrophages. Notably, intracellular concentrations 
of citrate, which itself inhibits glycolysis at the level of phosphofructokinase21, were 
substantially higher in mFamin–/– compared to mFamin+/+ macrophages differentiated 
under M1 conditions (Fig. 2l). Krebs cycle intermediates other than citrate remained 
indistinguishable between genotypes in M1 and M2 macrophages (Supplementary 
Fig. 5c), indicating absence of direct effects of FAMIN on Krebs cycle activity. 
Altogether, this indicates that the impairment in glycolysis may be a consequence of 
defective DNL. 
 
Mitochondrial FAO is promoted by FAMIN 
Since we had observed that the extent of carbon flux through DNL into acyl-Cn was 
determined by FAMIN, we hypothesized that FAMIN may control mitochondrial 
FAO. As expected, wild-type M2 macrophages had high basal OXPHOS, as reflected 
by high oxygen consumption rate (OCR), whereas M1 macrophages had low OCR 
that was refractory to oligomycin treatment, an inhibitor of ATP synthase (Fig. 3a–d). 
Impaired glycolysis usually leads to a compensatory increase in OXPHOS in order to 
maintain ATP intracellular concentrations22. However, in addition to defective 
glycolysis, mFamin–/– M1 and M2 macrophages also concomitantly exhibited 
significantly lower basal OCR compared to wild-type cells (Fig. 3a–d). Maximal 
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uncontrolled OCR (MU-OCR) is elicited by dissipating the mitochondrial 
electrochemical proton gradient with the ‘uncoupler’ carbonyl-cyanide p-tri-fluoro-
methoxy-phenyl-hydrazone (FCCP) and unmasks spare respiratory capacity (SRC)12. 
MU-OCR was reduced and SRC could not be elicited following uncoupling via FCCP 
in mFamin–/– M2 macrophages (Fig. 3b,e). Complete inhibition of mitochondrial 
respiration via rotenone and antimycin A, complex I and III inhibitors, respectively, 
abolished differences in OCR between mFamin–/– and mFamin+/+ macrophages (Fig. 
3a,b). Altogether these data demonstrate that mFamin–/– M1 and M2 macrophages 
exhibited reduced oxidative capacity in basal, but also uncoupled, respiratory states.  
 
High basal OCR and SRC in M2 macrophages has been reported to be secondary to 
FAO12. We therefore considered defective FAO as the cause for impaired oxidation, 
particularly apparent in mFamin–/– M2 macrophages. To test the hypothesis that 
FAMIN specifically affects mitochondrial FAO and not OXPHOS fuelled by other 
substrates, we inhibited CPT1a activity. Genetic silencing of Cpt1a, or blocking 
CPT1a with the irreversible inhibitor etomoxir23, decreased the OCR in mFamin+/+ 
cells to that observed in mFamin–/– M2 macrophages (Fig. 3f and Supplementary 
Fig. 5d). Importantly, silencing Cpt1a reduced basal ECAR in mFamin+/+ M1 and M2 
macrophages to the low levels seen in mFamin–/– macrophages, abrogating genotype-
dependent difference in glycolysis (Fig. 3g,h). In summary, our findings demonstrate 
that loss of FAMIN leads to decreased FAO that is needed to sustain high rates of 
glycolysis. 
 
FAMIN controls FAO of endogenously synthesized lipids 
Given that FAMIN controls carbon flux from glucose into acyl-CoA, we 
hypothesized that FAMIN may facilitate FAO of de novo synthesized fatty acids. 
Blockade of FASN function with the small molecule synthetic inhibitor C7524 
decreased basal OCR and SRC in mFamin+/+ M2 macrophages and abolished 
differences between mFamin+/+ and mFamin–/– cells (Fig. 3a–e). Importantly, 
blockade of FASN with C75 similarly decreased ECAR in M1 and M2 macrophages 
and abrogated mFamin genotype-related differences (Fig. 4a,b). To support this 
further, we measured OCR under conditions devoid of exogenous lipids, where FAO 
is thus entirely dependent upon de novo synthesized lipids by FASN. As before, 
baseline OCR and MU-OCR were decreased in mFamin–/– compared with mFamin+/+ 
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M2 macrophages, with differences abrogated by CPT1a inhibition with etomoxir 
(Fig. 4c). Supplementation of exogenous C16:0 increased basal and MU-OCR to 
equivalent levels in mFamin+/+ and mFamin–/– M2 macrophages (Fig. 4d), 
demonstrating that exogenous C16:0 can rescue depressed basal and maximum OCR 
in starved mFamin–/– M2 macrophages. Finally, blockade of CPT1a in M2 
macrophages supplemented with exogenous C16:0 decreased basal and MU-OCR to 
levels identical between mFamin+/+ and mFamin–/– cells (Fig. 4e). These data 
demonstrate that FAMIN supports FAO and glycolysis via a mechanism that involves 
DNL.  
 
FAMIN controls macrophage energy stores 
Considering that FAMIN controlled the extent of FAO and glycolysis in parallel and, 
remarkably, both processes did not cross-compensate for each other’s reduced 
function, we hypothesized that FAMIN function would impact on macrophage energy 
stores. Total cellular ATP was profoundly reduced by 30±12 % and 26±6 % in bone 
marrow-derived mFamin–/– compared to mFamin+/+ M1 and M2 macrophages (Fig. 
4f). Concentrations of cellular phosphocreatine, a rapidly mobilizable energy store, 
were similarly reduced as ATP in mFamin–/– compared to mFamin+/+ M1 and M2 
macrophages (Fig. 4g). Compared to mFamin+/+ macrophages, transmission electron 
microscopy (TEM) of mFamin–/– macrophages demonstrated morphological changes 
in mitochondria, characterized by elongation and narrowing, which are consistent 
with adaptation in response to ATP depletion (Fig. 5a,b)25. Hence FAMIN promotes 
glycolysis, FAO, and consequently cellular energy stores in macrophages. 
 
FAMIN determines macrophage ROS production  
Mitochondrial respiration generates reactive oxygen species (ROS) when electrons 
prematurely escape electron transport chain complexes I and III and react with 
molecular oxygen to generate superoxide anions26. Consistent with decreased 
mitochondrial oxidation in the absence of FAMIN, mitochondrial ROS (mROS) 
determined via a red-fluorescence mitochondrial superoxide indicator was profoundly 
reduced in mFamin–/– compared to mFamin+/+ M1 and M2 macrophages (Fig. 5c,d). 
Cytoplasmic ROS measured with the cytosolic ROS indicator, CM-H2DCFDA, was 
also lower in mFamin–/– M1, though unchanged between genotypes in M2 
macrophages (Supplementary Fig. 6a,b). Stimulation with the TLR2 agonist 
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zymosan resulted in significantly lower extracellular ROS (eROS) production in 
mFamin–/– compared to mFamin+/+ M1 and M2 macophages (Fig. 5e and 
Supplementary Fig. 6c). FASN inhibition with C75, or silencing of Fasn with 
siRNA, approximately halved eROS production in macrophages polarized under both 
M1 and M2 conditions, and abrogated the mFamin-associated differences (Fig. 5e 
and Supplementary Fig. 6c–e). CPT1a inhibition with etomoxir reduced zymosan-
elicited eROS generation in mFamin+/+ macrophages to levels observed in mFamin–/– 
cells, irrespective of whether the latter were treated with etomoxir (Fig. 5f and 
Supplementary Fig. 6f). A similar pattern of eROS production was observed upon 
Cpt1a silencing (Fig. 5g and Supplementary Fig. 6g) and, importantly, upon 
scavenging of mROS via mitoTEMPO (Fig. 5h and Supplementary Fig. 6h). As 
expected, eROS production was dependent on gp91phox NADPH oxidase27, since 
silencing the gene encoding gp91phox, Cybb, largely abrogated mFamin genotype-
related differences (Fig. 5i and Supplementary Fig. 6i). Remarkably, mFamin–/– 
macrophages exhibited decreased eROS generation despite increased NADPH being 
available (Supplementary Fig. 6j). In contrast to macrophages, PMA-elicited eROS 
production in murine neutrophils was independent of FAMIN (Supplementary Fig. 
6k), consistent with absent mFamin expression (6 and data not shown). In summary, 
FAMIN controls mROS production via a DNL- and FAO-dependent mechanism, and 
mROS, in turn, determines the NOX/DUOX system’s capacity to elicit eROS in 
macrophages. 
 
FAMIN.pI254V and pC284R exhibit impaired function 
We next determined whether the metabolic mechanisms elucidated above were 
affected by genetic variation in C13orf31. Wild-type C57BL/6N mice encode the 
human ‘risk’ G allele at the corresponding aa254 position, which we refer to as 
‘mFaminp254V’. Using CRISPR/Cas9, we introduced single nucleotide exchanges, 
generating mice homozygous for the leprosy/CD-protective [A] allele at aa254 
(‘mFaminp254I’, Supplementary Fig. 3)28. We also generated mice homozygous for 
the sJIA/EOCD-causing [C] allele at g.43,883,879, encoding aa284 (‘mFaminp284R’) 
instead of the normal [T] (‘mFaminp284C’, Supplementary Fig. 3). Metabolic flux 
analyses were equivalent between mFaminp284R and mFamin–/– macrophages, while 
mFaminp254I exhibited the highest ECAR, basal OCR and MU-OCR, and 
mFaminp254V macrophages intermediate levels (Fig. 6a–d). Consistent with such 
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decreased and loss of function of FAMIN.pI254V and FAMIN.pI284R, respectively, 
zymosan elicited higher eROS from mFaminp254I macrophages compared to 
mFaminp254V cells, while eROS production in mFaminp284R was similarly diminished 
as in mFamin–/– macrophages (Fig. 6e and Supplementary Fig 7a). Genotype-related 
differences between mFaminp254I and mFaminp254V in zymosan-elicited eROS 
production were abrogated upon inhibition of FASN with C75 (Fig. 6f and 
Supplementary Fig. 7b). Overexpression of human FAMIN.p254I under a CMV 
promoter in HEK293T cells yielded levels of protein indistinguishable from 
FAMIN.p254V (Fig. 6g), while expression of FAMIN.p284R was low and co-
localized with calreticulin, indicating retention in the ER (Fig. 6g, h). Altogether, our 
results demonstrate that p.C284R causes complete loss of function, while the single 
methyl group change p.I254V exhibits decreased function.  
 
We next obtained peripheral blood from healthy humans homozygous for the 
CD/leprosy risk (G/G; encoding FAMIN.p254V) and protective (A/A; encoding 
FAMIN.p254I) haplotypes identified by rs3764147. We isolated primary neutrophils 
and monocytes, and differentiated the latter in vitro into macrophages under M2 
conditions. C13orf31 mRNA expression in M2 macrophages was indistinguishable 
between the two haplotype groups (Supplementary Fig. 7c). Human M2 
macrophages homozygous for the risk haplotype exhibited decreased zymosan-
elicited eROS production compared to those homozygous for the protective haplotype 
(Fig. 6i). Human, in contrast to murine, neutrophils express FAMIN (5 and data not 
shown). PMA triggered lower ROS production in neutrophils with the risk- compared 
to the protective haplotype (Fig. 6j), extending decreased function of the risk 
haplotype beyond macrophages. These data demonstrate that the CD/leprosy risk 
haplotype is associated with decreased eROS production, hence consistent with 
results obtained with macrophages from SNP-edited mFamin.pI254V mice. Together, 
this identifies rs3764147 encoding FAMIN.pI254V as the causal genetic variation 
within this risk haplotype.  
 
FAMIN controls bactericidal and inflammasome activity 
Finally, we turned our attention to the consequences of this profound metabolic 
derangement on immune function. Mitochondrial ROS can directly augment the 
bactericidal activity of macrophages toward intracellular pathogens29. Compared to 
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mFamin+/+ cells, mFamin–/– M0 macrophages exhibited significantly decreased 
intracellular killing of a luminescent Mycobacterium bovis BCG strain30 (Fig. 7a). 
Silencing of C13orf31 in human macrophages resulted in reduced bactericidal activity 
towards luminescent M. bovis BCG (Fig. 7b), similar to murine macrophages. 
Finally, increased colony forming units (c.f.u.) of Salmonella enterica serovar 
Typhimurium were recovered from infected mFamin–/– compared to mFamin+/+ M0 
macrophages, irrespective of whether exogenous lipids were provided in serum or not 
(Fig. 7c), altogether demonstrating that FAMIN determines the capacity of 
macrophages to kill intracellular pathogens. 
 
Mitochondrial ROS also plays a critical role in caspase-1-mediated maturation of IL-
1b by the NLRP3 inflammasome31. This assembles on mitochondria-associated 
membranes (MAMs) upon triggering by pathogen-associated molecular patterns 
(PAMPs)31. NLRP3 inflammasome activation of mFamin–/– M1 macrophages with 
LPS + ATP resulted in lower levels of cleaved, active caspase-1p20 compared to 
mFamin+/+ cells, and consequently barely detectable cleaved IL-1bp17 in lysates and 
supernatants of mFamin–/– compared to mFamin+/+ M1 macrophages (Fig. 7d). 
Together, this demonstrates that FAMIN determines the capacity to trigger the 
NLRP3 inflammasome in M1 macrophages for the secretion of the host innate danger 
signal IL-1b. Moreover, FAMIN-dependent inflammasome activation was reliant 
upon intact FAO, as inhibition of FAO with etomoxir in LPS + ATP-stimulated wild-
type M1 macrophages resulted in lower levels of cleaved IL-1bp17 secretion (Fig. 
7e), as similarly observed in zymosan-stimulated M1 macrophages (Fig. 7f); no 
additive effect of FAO inhibition was observed in mFamin–/– M1 macrophages (Fig. 
7e). A similar pattern of FAO-dependent cytokine regulation was observed in LPS-
stimulated M1 macrophages for TNF and CXCL1, while IL-6 secretion remained 
unaffected (Fig. 7g–i). Importantly, intraperitoneal injection of 2 mg/kg LPS resulted 
in diminished IL-1b, CXCL1 and TNF serum levels in mFamin–/– compared to 
mFamin+/+ mice, while IL-6 levels remained unaffected (Fig. 8a–d). Notably, this 
pattern of LPS-induced serum cytokine regulation is reminiscent of inhibition of 
glycolysis in vivo with 2-DG11. 
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Upon stimulation with LPS or LPS + ATP in vitro, mononuclear cells from patients 
with sJIA exhibit profoundly diminished IL-1b secretion compared to cells from 
healthy individuals, although it had remained unclear whether this is cause or 
consequence of active disease or is related to therapeutics32. Considering that 
FAMIN.C284R is the only firmly established genetic cause of sJIA to date1, 33, 
hypomorphic IL-1b induction upon stimulation with LPS and ATP in vitro is hence 
notably consistent with our results in mFamin–/– M1 macrophages. Nonetheless, 
blocking of IL-1 is therapeutic in the vast majority of sJIA patients, leading to the 
swift normalization of fever, rash, and acute phase reactants32, 34, 35. We therefore 
hypothesized that the profound impairment in energetic reserve in the absence of 
FAMIN function (e.g. low ATP and phosphocreatine, mitochondrial injury, reduced 
FAO and glycolysis) might limit the organism’s capacity to withstand serious injury. 
We injected a high dose of LPS (10 mg/kg) intraperitoneally, and continuously 
surveyed mFamin–/– and mFamin+/+ mice over a 3h period for clinical signs of sepsis. 
mFamin–/– mice exhibited higher sepsis scores (not covered by these scores, 2 out of 7 
mFamin–/– mice also showed signs of epistaxis consistent with bleeding disorder, not 
observed in mFamin+/+ mice), particularly apparent during the first 90 minutes (Fig. 
8e). This was associated with a more than 2-fold increase in IL-1b serum levels at the 
conclusion of the experiment (Fig. 8f). Turning to SNP-mutant mice, 10 mg/kg LPS 
resulted in highest IL-1b serum levels in mFaminp254V-284R mice, intermediate levels 
in mFaminp254V-284C mice, and lowest in mFaminp254I-284C mice as depicted in Fig. 8g. 
Correspondingly, mFaminp254V-284R mice exhibited higher clinical sepsis scores 
compared to mFaminp254V-284C, and mFaminp254V-284C higher than mFaminp254I-284C 
mice (Fig. 8h,i). Altogether, this demonstrates that in the absence of FAMIN 
function, high-dose LPS leads to catastrophic IL-1b activation. It can be speculated 
that the impaired bioenergetic reserve of mFamin–/– mice might tip the balance of 
sepsis-associated inflammasome activation towards a pyroptotic, pro-death response 
as has been reported in other contexts36. 
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Discussion 
At an organismal level, fatty acid and glucose oxidation are reciprocal metabolic 
pathways, referred to as the Randle cycle37. Similarly, coupling of DNL and FAO is 
not energetically efficient in terms of ATP production, but nonetheless engaged in 
certain immune and non-immune cells38, 39, 40. In macrophages, FAMIN promotes flux 
through DNL to concomitantly drive high levels of both FAO and glycolysis. FAMIN 
thereby profoundly determines the maximum bioenergetic capacity of macrophages. 
Belonging to a new class of proteins (domain of unknown function 152 [DUF152] 
family), the closest orthologues of FAMIN with a reported function are bacterial 
proteins that exhibited atypical laccase (phenol oxidoreductase) activity41, 42. We 
purified recombinant eukaryotically expressed human FAMIN.p254I and 
FAMIN.p254V, and did not observe any laccase activity toward a series of 
prototypical substrates (data not shown). At this stage, it remains unclear how 
precisely FAMIN enhances DNL-dependent FAO. 
 
Intriguingly, FAMIN-dependent FAO occurs even when uncoupled from ATP 
synthesis as in M1 macrophages, and may be of greatest importance in this setting for 
supporting glycolysis. ‘Uncoupled’ FAO has been suggested to have a critical role in 
cancer cells engaged in aerobic glycolysis43. Moreover, inhibition of DNL at the level 
of Acetyl-CoA carboxylase 1 (ACC1), the enzyme synthesising malonyl-CoA 
required for FASN function, has been reported to impair glycolysis in T helper cells44. 
As a consequence, we uncover a critical role of FAO in M1 macrophages that is 
required for IL-1b activation and ROS production. Glycolysis in M1 macrophages is 
well known to be critically required for IL-1b production11. By contrast, the 
importance of b-oxidation has received less attention even though FAO, not 
glycolysis, has been reported as the sole driver of bactericidal mROS production in 
Salmonella-infected macrophages45. Moreover, FAMIN-dependent mROS production 
also determines the maximum capacity of the NOX/DUOX oxidase system, the major 
bactericidal ROS source in M1 macrophages. 
 
While metabolic pathways in bona fide immune cells are emerging as important 
determinants of immune function46, this is the first demonstration that a core 
metabolic regulator in immune cells is affected by genetic variation that causes, or 
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predisposes for, immune-related disease and infection. Systemic JIA, which we 
demonstrate arises from a defect at the peroxisome – mitochondria interface, presents 
with a characteristic daily spiking (‘quotidian’) fever33. Deficiency in mevalonate 
kinase, a peroxisomal enzyme involved in cholesterol biosynthesis, causes a related 
juvenile periodic fever, hyper-IgD syndrome47. Remarkably, the mevalonate pathway 
has a common precursor with DNL, cytosolic acetyl-CoA, raising the possibility of 
commonality in mechanism. Intriguingly, both sJIA and hyper-IgD syndrome appear 
to be triggered by childhood infections or vaccinations33, 47. Diversity in such 
environmental triggers may also explain how homozygosity for p.C284R loss-of-
function can cause two very different diseases, sJIA and EOCD1, 2, an aspect even 
more pertinent for the hypomorphic p.I254V, which predisposes for CD. 
 
In summary, we report that FAMIN controls acyl-CoA synthesis through DNL at 
peroxisomes, thereby feeding FAO and regulating glycolysis. This has profound 
implications for cellular energy homeostasis and organismal immune function, with 
hypomorphy promoting autoinflammation. 
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METHODS  
Methods and any associated references are available in the online version of the 
paper.  
 
Note: Any supplementary information and source data files are available in the online 
version of the paper. 
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Main Figure Legends 
 
Figure 1: FAMIN interacts with fatty acid synthase and localizes to peroxisomes 
(a) Immunoblots (IB) for FAMIN and FASN after anti-C13orf31, anti-FASN or IgG 
control immunoprecipitation (IP) of primary human PBMC-derived and PMA-
differentiated U937 and THP-1 macrophages (MF). (b) Proximity-ligation assay 
(PLA) of FAMIN  and FASN (yellow) in THP-1 macrophages. DAPI, blue; scale bar 
= 5 µm. (c) IB for FAMIN of lysates and after anti-FASN IP of HEK293 expressing 
FAMIN.p254I  or FAMIN.p254V; GAPDH loading control. (d) Co-localization by 
immunofluorescence (IF) of FAMIN (red) with PMP70 (green) in primary human 
macrophages. DAPI nuclear staining, blue; scale bar = 5 µm. Images are enlarged 
from the demarcated region in Supplementary Fig. 2a; rightmost panel represents 
further enlargement of the area shown in the white box. (e) PLA of FAMIN and 
PMP70 (red) in THP-1 macrophages. DAPI, blue; scale bar = 5 µm. (f,g) Co-
localization by IF of FASN (red) with catalase (green) in M1 and M2 macrophages. 
DAPI, blue; scale bar = 5 µm. (h,i) PLA of FASN and catalase (yellow) in M1 and 
M2 macrophages. DAPI, blue; scale bar = 5 µm. Data are representative of three 
independent experiments (a–e) or one experiment with three mice and six (f,g) or ten 
(h,i) cells imaged per sample (f–i; mean ± S.E.M.).  
 
Figure 2: FAMIN promotes glycolysis and glucose flux into de novo lipogenesis. 
(a–d) Measurement of 13C-labelled C16:0 and C18:1 fatty acyl CoA following a 24 h 
pulse with 1,2-13C-glucose in mFamin–/– and mFamin+/+ M1 and M2 macrophages 
(MF). (e,f) Measurement of total fatty acyl CoA in M1 and M2 macrophages. (g,h) 
Measurement of 13C-labelled C16:0 and total fatty acyl carnitine (FaCN) following a 
24 h pulse with 1,2-13C-glucose in M2 macrophages. (i–k) Extracellular rate (ECAR) 
of M0, M1 and M2 macrophages given sequential treatment (dotted vertical lines) 
with oligomycin (Oligo) and 2-deoxyglucose (2-DG). (l) Citrate levels in M1 and M2 
macrophages. Each	symbol (a–h, l) represents an individual mouse; small horizontal 
lines and error bars indicate the mean ± S.E.M. *P < 0.05, **P < 0.01, *** P < 0.001 
(Unpaired, two-tailed Student’s t-test; Grubb’s test outlier exclusion). Data are from 
one experiment with six (a–h) or seven mice (l) or one experiment with three mice 
representative of three independent experiments (i–k; mean ± S.E.M.).  
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Figure 3: FAMIN augments fatty acid oxidation. 
(a,b) Oxygen consumption rate (OCR) of mFamin–/– and mFamin+/+ M1 and M2 
macrophages (MF) ± 20 µM C75 followed by sequential treatment (dotted vertical 
lines) with oligomycin (Oligo), FCCP, and rotenone plus antimycin (Rot + ant). 
Spare respiratory capacity (SRC) as depicted and refers to difference between 
maximal and basal respiratory capacities. (c–e) Basal respiratory and maximal 
respiratory capacity in M1 macrophages (n = 6) and M2 macrophages ± C75 (n = 
14/13/9/7). (f–h) OCR and extracellular acidification rate (ECAR) of M1 and M2 
macrophages silenced for Cpt1a (Cpt1a siRNA) or scrambled siRNA (Ctrl siRNA). 
*P < 0.05, **P < 0.01 (Unpaired, two-tailed Student’s t-test). Data are from one 
experiment with three mice representative of three independent experiments (a,b,f–h; 
mean ± S.E.M.) or pooled from two or more independent experiments (c–e; mean ± 
S.E.M.).  
 
Figure 4: FAMIN controls FAO of endogenously synthesized lipids 
(a,b) Basal ECAR of mFamin–/– and mFamin+/+ M1 and M2 macrophages (MF) ± 20 
µM C75. (c–e) OCR of M2 macrophages cultured in serum free medium and treated 
as indicated with 40 µM etomoxir (ETO) for 1 h and supplemented with bovine serum 
albumin (BSA) conjugated palmitate (PALM) or BSA alone prior to OCR 
measurement. (f) ATP quantification in M1 and M2 macrophage lysates (n = 8). (g) 
Phosphocreatine (PCr) levels in M1 and M2 macrophages. Each	symbol (f,g) 
represents an individual mouse; small horizontal lines and error bars indicate the 
mean ± S.E.M. *P < 0.05, **P < 0.01 (Unpaired, two-tailed Student’s t-test). Data are 
from one experiment with three mice representative of three independent experiments 
(a–e; mean ± S.E.M.) or from one experiment with eight (f) or seven mice (g).    
 
Figure 5: FAMIN-deficient macrophages have impaired mitochondrial ROS 
production and exhibit features of mitochondrial injury and remodeling. 
(a) Transmission electron microscopy of M1 and M2 macrophages (MF) showing 
mitochondria; black arrowheads show mitochondria that are elongated and amorphous 
in mFamin–/– M1 macrophages and narrower in mFamin–/– M2 macrophages 
compared to mFamin+/+ controls (white arrowheads). N = nucleus, scale bar = 1 µm 
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and (b) quantification of mitochondrial size. (c,d) Mitochondrial ROS in unstimulated 
mFamin–/– and mFamin+/+ M1 and M2 macrophages stained with a red fluorescent 
mitochondrial superoxide indicator and measured in relative fluorescence units, RFU. 
(e–i) Zymosan induced ROS production in mFamin–/– and mFamin+/+ M1 
macrophages treated as indicated for 16 h with 20 µM C75; or 1 h with 40 µM 
etomoxir (ETO) or 500 µM mitoTEMPO prior to stimulation; or silenced for Cpt1a 
(Cpt1a siRNA) or Cybb (Cybb siRNA) or scrambled siRNA (Ctrl siRNA); Left, ROS 
kinetic plots measured in relative light units, RLU and right, area under curve, AUC. 
*P < 0.05, **P < 0.01 (Mann–Whitney U-test (b) or unpaired, two-tailed Student’s t-
test (c–f,h)). Data are representative of one experiment with three mice and six cells 
imaged per sample (a–b; mean ± S.E.M.) or from one experiment with three mice 
representative of at least two independent experiments (c–i; mean ± S.E.M.). 
 
Figure 6: FAMIN.pI254V is hypomorphic and FAMIN.pC284R leads to 
complete loss of function.  
(a–d) Extracellular rate (ECAR) and Oxygen consumption rate (OCR) in murine M1 
and M2 macrophages (MF) from mFamin–/– and C57BL/6N mice natively 
homozygous for the human ‘risk’ rs3764147 [G] allele (‘mFaminp254V’) or ‘non-risk’ 
[A] allele (‘mFaminp254I’) or Mendelian ‘risk’ variant (‘mFaminp284R’) at 
corresponding nucleotides of the murine gene. (e) Zymosan-stimulated ROS 
production in mFaminp254I, mFaminp254V, mFaminp284R and mFamin–/– M1 
macrophages measured in relative light units, RLU. (f) Zymosan induced ROS 
production in  mFaminp254I and mFamin p254V M1 macrophages treated as indicated 
for 16 h with 20 µM C75. (g) Immunoblot (IB) for FAMIN and Strep-tag in HEK293 
cells with stable expression of N-terminal Strep-tagged FAMIN.p254I, 
FAMIN.p254V, FAMIN.p284R or vector control; b-actin loading control. (h)  Co-
localization by immunofluorescence of FAMIN (green) and calreticulin (red). DAPI, 
blue; scale bar = 5 µm. (i) Zymosan-stimulated ROS production in PBMC-derived 
M2 macrophages from healthy donors homozygous for the Crohn’s disease and 
leprosy risk (‘rs3764147G/G’) and non-risk (‘rs3764147A/A’) haplotypes; n = 10. (j) 
PMA-stimulated ROS production in neutrophils; Left, ROS kinetic plots and right, 
area under curve/peak height. Each symbol (i,j) represents an individual donor; small 
horizontal lines and error bars indicate the mean ± S.E.M. *P < 0.05, **P < 0.01 
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(Unpaired, two-tailed Student’s t-test). Data are from one experiment with three mice 
representative of two independent experiments (a–f; mean ± S.E.M), representative of 
three independent experiments (g,h) or pooled from 10 independent experiments (i,j). 
 
Figure 7: FAMIN deficiency causes defective bacterial clearance and 
inflammasome activation, in vitro. 
(a) mFamin–/– and mFamin+/+ M0 macrophages (MF) infected with Bacillus Calmette 
Guérin (BCG), containing a luciferase reporter gene; relative light units (RLU) 
measured at 0, 4, or 24 h. (b) Infection with BCG of human PBMC-derived M0 
macrophages, silenced for FAMIN or scrambled siRNA control. (c) mFamin–/– and 
mFamin+/+ M0 macrophages infected with S. Typhimurium SL1344 in either serum 
containing or serum free medium; colony forming units, CFU. (d) Immunoblot (IB) 
of IL-1b and caspase 1 from mFamin–/– and mFamin+/+ M1 macrophages cell lysates 
(Lys) and supernatants (Sup); b-actin loading control. M1 macrophages were 
pretreated with 500 ng/mL of LPS for 2 h in serum free media and stimulated for 15 
min with ATP. (e) IB of IL-1b in M1 macrophage cell supernatants; macrophages 
were pretreated as in (d) ± 100 µM etomoxir (ETO). (f) IL-1b levels in supernatants 
of M1 macrophages stimulated with 200 µg/mL of zymosan, pre-treated for 2 h with 
100 µM etomoxir (ETO). (g–i) TNF, CXCL1 and IL-6 levels in supernatants of  M1 
macrophages stimulated with 1µg/mL of LPS pre-treated for 2 h with 100 µM 
etomoxir (ETO). *P < 0.05, **P < 0.01 (One-way ANOVA with post-hoc Bonferroni 
(a,b) or unpaired, two-tailed Student’s t-test (c,f–i)). Data are from one experiment 
with three mice representative of three independent experiments (a,d–i; mean ± 
S.E.M.) or from one experiment with six independent samples per group (b,c; mean ± 
S.E.M.).  
 
Figure 8: FAMIN deficiency causes dysregulated response to endotoxin in vivo. 
(a–d) IL-1b, TNF, CXCL1 and IL-6 serum levels 2 h after intraperitoneal (i.p.) 
injection of LPS (2 mg/kg) of mFamin–/– and mFamin+/+ mice. (e) Clinical scoring of 
sepsis severity (maximum score 15) and (f) IL-1b serum levels 3 h after i.p. injection 
of LPS (10 mg/kg) of  mFamin–/– and mFamin+/+ mice. (g) IL-1b serum levels 3 h 
after i.p. injection of LPS in 5 week-old mice homozygous for mFaminp254I-284C and 
their homozygous littermate mFaminp254V-284C controls; and homozygous 
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mFaminp254V-284R mice and their homozygous mFaminp254V-284C littermate controls; 
(h,i) clinical scores of sepsis severity (maximum score 15). Each symbol (a–d,g) 
represents an individual mouse; small horizontal lines and error bars indicate the 
mean ± S.E.M. *P < 0.05, **P < 0.01 (Unpaired, two-tailed Student’s t-test (a–d,f,g) 
or linear mixed model (e,h,i)). Data are from one experiment with four mice per 
group (a–d), three mice per group (e,f; mean ± S.E.M.) or seven (mFaminp254I-284C), 
four (mFaminp254V-284C, mFaminp254V-284C) or five (mFaminp254V-284R) mice (g–i; mean 
± S.E.M.).  
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ONLINE METHODS 
 
Mice. 
Ear biopsy genomic DNA was used for routine genotyping of all mice. Primer 
sequences are shown in Supplementary table 3. C57BL/6N mice were bred and 
maintained in specific pathogen-free conditions at the Central Biomedical Services 
(CBS) facility, University of Cambridge and at the Wellcome Trust Sanger Institute. 
All procedures performed in studies involving animals were in accordance with the 
ethical standards of the institution or practice at which the studies were conducted and 
conducted with approval of the UK home office. mFamin–/–, mFaminp284R and 
mFaminp254I mice generated as described below littered at Mendelian ratios, 
developed normally, and no spontaneous disease emerged under specific pathogen 
free (SPF) conditions. Six to twelve week-old mice that were age and sex-matched as 
described in the relevant methods sections were used for all experiments unless 
otherwise stated.  
mFamin–/– allele.  
mFamin–/– mice were generated by disruption of the mouse homologue of human 
C13orf31 (9030625A04Rik) by homologous recombination in C57BL/6N-A/a 
embryonic stem (ES) cells (Supplementary Fig. 3) to generate mice on a pure 
C57BL/6NTac background; ES cell clone ID EPD0538_1_D06 (International 
Knockout Mouse Consortium)13.	
CRISPR/Cas9 target sites and vector construction. 
CRISPR target sites were identified using http://crispr.mit.edu/ as described28 and are 
shown in Supplementary Table 4. The strategy to generate mouse lines carrying the 
p.254V and p.284R FAMIN disease associated variants (corresponding residue 
numbers are identical between human C13orf31 and murine 9030625A04Rik) is 
shown in Supplementary Fig. 3. In brief, wild-type C57BL/6NTac mice carry 
p.254V (human ‘risk’ variant) and p.284C. For introduction of the ‘non-risk’ p.254I 
allele, guide RNA (gRNA) ‘line7’ along ‘oligo 7’ or ‘oligo 7 wobble’ were used, the 
latter introducing two additional synonymous nucleotide changes (Supplementary 
Table 4 and Supplementary Fig. 3). The corresponding strategy for introduction of 
the ‘Mendelian variant’ p.284R with gRNA ‘line9’ along ‘oligo 9’ or ‘oligo 9 
wobble’ is shown in Supplementary Fig. 3. Oligonucleotide tyrex2R 
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(Supplementary Table 4) was co-injected with each of the four lines to target the Tyr 
gene, allowing for color-based selection. The selected gRNA sequences were cloned 
into a gRNA vector containing the gRNA backbone and a T7 promoter to facilitate 
RNA production (BsaI sites). Cas9 mRNA was produced using a previously described 
vector modified to contain a T7 promoter48. The integrity of all plasmids was 
confirmed by DNA sequencing. The targeting oligonucleotides were synthesized as 
desalted ssDNA oligonucleotides from Integrated DNA Technologies (IDT).   
Cas9 and gRNA production. 
For Cas9 RNA production the T7/Cas9 plasmid was linearized (EcoRI), purified with 
PCR purification kit (Qiagen) and in vitro transcribed using mMessage mMachine T7 
Ultra kit (Life Technologies). For gRNA production the plasmid was linearized 
(DraI), purified with PCR purification kit (Qiagen) and in vitro transcribed using the 
MEGAshortscript T7 kit (Life Technologies). Both, Cas9 mRNA and gRNA, were 
purified using the MEGAclear kit (Life Technologies) and eluted in RNase-free 
water. The quality of the RNA was analyzed using Agilent RNA 6000 Nano kit 
(Agilent Technologies, 2100 Bioanalyzer) and Qubit RNA HS assay kit (Life 
Technologies). 
One-cell embryo injection. 
Twelve 4-5 week old C57BL/6NTac females were super-ovulated by intraperitoneal 
(i.p.) injection of 5 IU of pregnant mare’s serum (PMSG) at 12:00-13:00 h (on a 12 h 
light/dark cycle, on at 07:00/off at 19:00) followed 48 h later by an i.p. injection of 5 
IU human chorionic gonadotrophin (hCG) and mated overnight with C57BL/6NTac 
stud males. The next morning the females were checked for the presence of a vaginal 
copulation plug as evidence of successful mating and oviducts were dissected at 
approximately 21-22 h post hCG. Cumulus oocyte complexes from these were 
released and treated with hyaluronidase as previously described and the fertilized 1-
cell embryos were left in KSOM media ready for cytoplasmic injection49. 50 ng/µl 
Cas9 mRNA, 25 ng/µl gRNA and 100 ng/µl oligonucleotide were mixed in RNase-
free water and injected into the cytoplasm of fertilized 1-cell embryos in FHM 
medium. 1-cell injected embryos were transferred the same day by oviductal embryo 
transfer into 0.5 days post-coital pseudo-pregnant female BJCB strain 
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(CBA<Wtsi>;C57BL/6J-Jax F1) recipients, produced by estrus selecting and 
overnight mating to vasectomized males49.  
Cytoplasmic injections. 
Injections were performed using a new cytoplasmic injection technique. An injector 
using a positive balance pressure such as an Eppendorf Femtojet was connected to a 
microinjection tip filled with the CRISPR materials. The microinjection tip was 
steadily advanced towards the opposite side of the oocyte, which was anchored by the 
holding pipette until the micropipette passed through the plasma membrane to break 
it. The pipette was then drawn back into the cytoplasm, the CRISPR mix delivered 
and the micropipette immediately withdrawn. A successful injection was indicated by 
visible movement in the cytoplasm. 
 
SNP mutant mice breeding strategy 
Illumina sequencing of the mFamin gene was used in founder and F1 generation 
mice, confirmed by Sanger sequencing, to assess for successful gene editing. Founder 
mice were crossed with wild-type C57BL/6NTac mice to generate mFaminp254I/p254V 
and mFaminp284R/p284C heterozygous mice, which were then intercrossed, and 
homozygous littermates used for experiments. Mice generated with and without 
wobble bases in targeting oligonucleotides were maintained separately, and used in 
experiments alongside their littermate controls irrespective of the presence or absence 
of wobble bases. Offspring from several founders were used to populate genotype 
categories in experiments. Routine genotyping was performed via Sanger sequencing. 
 
Genotype-selected human samples. 
Peripheral blood for human neutrophil and monocyte isolation was collected from 
healthy volunteers from a genotype-selectable bioresource of ~10,000 individuals 
(Cambridge BioResource [CBR], http://www.cambridgebioresource.org.uk). Healthy 
age- and sex-matched individuals identified as homozygous for the risk (G/G) and 
non-risk (A/A) haplotype at the C13orf31 nsSNP rs3764147, encoding p.254V and 
p.254I respectively, were recruited to participate in the study. None of the volunteers 
had received corticosteroid or immunosuppressant therapy within 6 months of 
enrollment. Investigators were kept blinded to the genotype of samples until study 
completion, with all individual experimental procedures performed on (blinded) 
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genotype pairs. The study protocol has been reviewed and approved by the Berkshire 
B Research Ethics Committee (15/SC/0068), and written informed consent was 
obtained from each subject. 
 
Antibodies and reagents. 
The following antibodies were used for immunoblotting. Abcam: anti-PMP70 
(1:1,000 dilution; ab3421), anti-FASN (1µg/ml dilution; ab22759); Cell Signaling: 
anti-cytochrome oxidase IV (1:250 dilution; 4850), anti-catalase (1:800 dilution; 
12980), anti-centromere protein A (1:400 dilution; 2186), anti-calreticulin (1:200 
dilution; 12238), anti-FASN (1:1,000 dilution; 3180); Santa Cruz Biotechnology: 
anti-C13orf31 (1:200 dilution; sc-374553; E7 and 1:500 dilution; sc-376231; E12), 
anti-caspase 1 p20 (1:250 dilution; sc-1218-R); R&D Systems: anti-IL-1b (1:250 
dilution; AF-401-NA); Sigma: anti-b-actin (1:10,000 dilution; A5060). All antibodies 
used have validation profiles on either Antibodypedia or 1DegreeBio. 
 
The following reagents were used: M-CSF (Peprotech, 300-25), LPS (from 
Escherichia coli K12, InvivoGen, tlrl-peklps), human IFN-g (Peprotech, 300-02), 
murine IFN-g (Peprotech, 315-05), human IL-4 (Peprotech, 200-04), murine IL-4 
(Peprotech, 214-14), ATP (Sigma Aldrich, A2383), C75 (Sigma Aldrich, C5490), 
etomoxir (Sigma Aldrich, E1905), MitoTEMPO (Sigma Aldrich, SML0737), 
oligomycin (Sigma Aldrich, O4876), FCCP (Sigma Aldrich, C2920), rotenone (Sigma 
Aldrich, R8875), antimycin A (Sigma Aldrich, A8674), palmitate-BSA (Seahorse 
Bioscience, 102720-100), zymosan A (Sigma Aldrich, Z4250), PMA (Sigma Aldrich, 
P1585), HRP (Sigma Aldrich, P8375), luminol (Sigma Aldrich, A8511).  
 
Murine bone marrow-derived macrophages and neutrophils 
Bone marrow was flushed from mouse femurs and tibias, filtered through a 70 µm 
cell strainer and incubated in complete medium (RPMI-1640 containing 100 U/ml of 
penicillin-streptomycin, 1 mM HEPES pH 7.4) and 10% FBS. Bone marrow derived 
macrophages (BMDMs) were prepared by culturing cells for 6 days in the presence of 
100 ng/ml of M-CSF. After harvesting and re-seeding, Macrophages were polarized 
for 16 h toward M1 and M2 with IFN-g (50 ng/ml) plus LPS (20 ng/ml) and IL-4 (20 
ng/ml), respectively, and where indicated, in the presence or absence of C75 (20 µM) 
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and etomoxir (100 µM). Bone marrow neutrophils were prepared using a neutrophil 
isolation kit (Miltenyi Biotec) according to manufacturer’s instructions. 
 
Human peripheral blood-derived macrophages  
For studies with human cells, blood received from healthy donors was used to isolate 
peripheral blood mononuclear cells and neutrophils by Lymphoprep (Axis-Shield) 
gradient centrifugation. Monocyte-derived macrophages were generated by 
resuspending cells in complete RPMI-1640 and plated on Nunclon surface tissue 
culture dishes (Nunc). After 2 h, non-adherent cells were discarded and the remaining 
monocytes cultured for 4 days in complete medium with 10% FBS and 40 ng/ml M-
CSF. At day 4, macrophages were harvested and polarized into M1 and M2 as 
described for murine macrophages. Neutrophils were concurrently isolated during 
Lymphoprep gradient centrifugation (Axis-Shield) by sedimentation of the red blood 
cell/neutrophil layer with 10% dextran, followed by hypotonic lysis of contaminating 
erythrocytes.  
 
Cell lines 
THP-1 and U937 cell lines were maintained in complete RPMI-1640 with 10% FBS. 
To polarize into M1 macrophages, cells were incubated overnight with 50 ng/ml IFN-
g plus 20 ng/ml LPS and for M2 macrophages, cells were treated with 1 µM of PMA 
for 6 h and then polarized with 50 ng/ml IL-4 and 50 ng/ml IL-13. HEK293 and 
HEK293T cells were maintained in DMEM with 10% FBS. All cell lines were 
purchase from ATCC, which guarantee cell line authentication. 
 
Plasmids 
FAMIN was amplified from an IMAGE clone (MHS1010-7508636) using a forward 
primer containing a KpnI site followed by a Kozak sequence and start codon and 
reverse primer containing a BamHI site, excluding the stop codon of FAMIN and was 
cloned into KpnI and BamHI digested and dephosphorylated pEXPR-IBA103 (IBA 
Life Sciences) to generate C-terminal Strep III tag FAMIN. The same IMAGE clone 
was amplified with a forward primer containing a SacII site and a reverse primer 
containing an XhoI site and cloned into pEXPR-IBA105 to generate N-terminal Strep 
III tag FAMIN. Strep-tag III is a sequential arrangement of two Strep-tag II sequences 
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(Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) separated by a short linker. Constructs were 
sequence verified, with Strep-tag III in-frame withFAMIN. FAMIN containing a stop 
codon was also cloned into pEXPR-IBA103 for use as an untagged FAMIN control. 
FAMIN variants were introduced by site-directed mutagenesis (Agilent Quick change 
II XL SDM kit) using the above constructs as template. To introduce the p.254V 
mutation the following primers were used: Forward, 5′-
AGACTCATCATTCCAATGACGTCTGGATTATGGGAAGAAAG-3′; Reverse, 5′-
TAAAGACTCATCATTCCAATGACATCTGGATTATGGGAAGAAAGGAG-3′ 
and to introduce the p.284R mutation the following primers were used: Forward, 5′-
CAAAAACTATCGGTATACGGTCTGCACCAAGAGCTGC-3′; Reverse 5′-
GCAGCTCTTGGTGCAGACCGTATACCGATAGTTTTTG-3′. All constructs were 
sequence verified in both forward and reverse orientations. 
 
Protein affinity-purification mass spectrometry. 
HEK293T cells were transfected with pEXPR-IBA103 vector only, untagged FAMIN, 
N-terminal Strep-tag FAMIN or C-terminal Strep-tag FAMIN plasmid constructs 
using Lipofectamine 2000 (Invitrogen) following manufacturer's instructions. 48 h 
following transfection, cells were washed twice in ice-cold PBS and harvested by 
gently scraping into 5 ml ice-cold lysis buffer containing 20 mM HEPES-KOH, pH 
7.5, 150 mM KCl, 1% Nonidet P-40, 0.1 mM phenylmethylsulfonyl fluoride, and 
protease inhibitor mixture. Cells were incubated on ice for 10 min then homogenized 
by shearing 20 times through a 21-gauge needle. The protein lysate was centrifuged 
for 15 min at 4 °C at 3,000g and protein supernatant collected into a freshly chilled 
tube to remove cellular debris. 1 U/ml of avidin was added to block endogenous 
biotin and incubated on ice for 15 min and then re-centrifuged for a further 10 min at 
4 °C. Supernatant containing strep-tag labeled FAMIN protein was pulled down using 
a Strep-Tactin column (IBA Life Sciences). Strep-tagged FAMIN protein complexes 
were eluted using 2.5 mM desthiobiotin and eluted fractions were subjected to SDS-
PAGE separation followed by silver stain or immunoblot. Gels were submitted to the 
Cambridge Centre for Proteomics, Department of Biochemistry and were excised 
manually. Proteins were reduced, carboxyamide methylated, and then digested to 
peptides using trypsin on a MassPrepStation (Micromass). The resulting peptides 
were applied to liquid chromatography coupled with tandem mass spectrometry (LC-
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MS/MS) on a QTof (Micromass). Fragmentation data were used to search the 
National Center for Biotechnology Information database using the MASCOT search 
engine (http://www.matrixscience.com) 
 
Lipid mass spectrometry. 
Day-6 macrophages were seeded at 5 × 106 cells per 60 mm dish and polarized under 
M1 or M2 conditions. Cells were harvested, washed twice in ice-cold PBS and then 
flash frozen in liquid nitrogen. For 1, 2-13C-glucose–tracing experiments, 
macrophages were polarized overnight and then cultured for 24 h in the presence of 
10 mM 1,2-13C-glucose (Sigma). Cell pellets were washed twice with cold PBS and 
re-suspended in 1.5 ml methanol. After spiking with 40 µl lipid standards cocktail 
mix of 50 ng 17:0-FaCN, 100 ng 17:0-FaCoA and 400 ng 17:0-FFA, 1.5 ml of 
LCMS-grade water and 3 ml chloroform were added in. The mixture was subjected to 
Folch extraction. After collection of the lower phase, the upper phase was re-extracted 
with 3 ml synthetic lower phase (chloroform/methanol/water at volume ratio of 2:1:1, 
using the lower phase for re-extraction of lipid). The lower phase from both 
extractions was combined and dried under vacuum at 20 °C with SpeedVac (Thermo) 
and re-dissolved in 100 µl chloroform. 7 µl were injected for LC/MS/MS analysis. A 
Thermo Orbitrap Elite system (Thermo Fisher) hyphenated with a five-channel online 
degasser, four-pump, column oven, and autosampler with cooler Shimadzu 
Prominence HPLC system (Shimadzu) was used for lipid analysis. In detail, lipid 
classes were separated on a normal phase silica gel column (150  × 2.1 mm, 4 µm, 
MicoSolv Technology) with 
hexane/dichloromethane/chloroform/methanol/acetanitrile/water/ethylamine solvent 
gradient based on the polarity of head group. High resolution (240k at m/z 400) / 
accurate mass (with mass accuracy <5 ppm) were used for molecular species 
identification and quantification. The identity of lipid was further confirmed by 
reference to appropriate lipids standards. Orbitrap Elite mass spectrometer operation 
conditions: A. For positive ion analysis, Heated ESI Source in positive ESI mode, 
Heater Temperature: 325 C, Sheath Gas Flow Rate (arb): 35, Aux Gas Flow Rate 
(arb): 5, Sweep Gas Flow Rate (arb): 0, I Spray Voltage: 3.5 kV, Capillary 
Temperature: 325 C, S-Lens RF Level: 60%. Orbitrap mass analyzer was operated as 
SIM scan mode with two events. Event 1, mass range: m/z 238-663, mass resolution: 
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240 k at m/z 400. Event 2, mass range: m/z 663-1088, mass resolution: 240 k at m/z 
400. B. For negative ion analysis, Heated ESI Source in negative ESI mode, Heater 
Temperature: 325 C, Sheath Gas Flow Rate (arb): 45, Aux Gas Flow Rate (arb): 10, 
Sweep Gas Flow Rate (arb): 0, I Spray Voltage: 3.0 kV, Capillary Temperature: 375 
C, S-Lens RF Level: 70%. Orbitrap mass analyzer was operated as SIM scan mode 
with two events. Event 1, mass range: m/z 218-628, mass resolution: 240 k at m/z 
400. Event 2, mass range: m/z 628-1038, mass resolution: 240 k at m/z 400. All the 
solvents used for lipids extraction and LC/MS/MS analysis are LC-MS grade from 
FisherScientific. 
 
Aqueous metabolites mass spectrometry 
Metabolites were extracted from 5 × 106 macrophages using methanol/chloroform. 
The organic and aqueous fractions were separated by the addition of water and 
chloroform. The aqueous layer was analyzed subsequently for metabolomics. Mass 
spectrometry was performed on an AB Sciex 5500 (Warrington) coupled to an 
Acquity ultra performance liquid chromatography (UPLC) system from Waters Ltd. 
For chromatography of Krebs cycle intermediates metabolites were separated on a 
BEH amide HILIC column (100 × 2.1 mm, 1.7 µm; Waters Ltd) in negative ion 
mode. After drying, the samples were analyzed on a HSS T3 column (100 × 2.1 mm, 
1.7 µm; Waters Ltd). Cone voltage, collision energy and mass transitions were 
optimized for each metabolite for quantification. Data are expressed in arbitrary units 
as the area ratio of metabolite peak relative to the internal standard.   
 
ATP assay 
ATP content in total cell lysates was measured using an ATP determination kit 
(Molecular probes, A22066). Briefly, M1 and M2 macrophages were trypsinized after 
an overnight polarization, counted and 2 × 105 cells were lysed in 100 mM Tris pH 
7.75, 4 mM EDTA and 1% Triton-X. Protein concentration was determined by BCA 
(Pierce, 23225). Remaining lysates were boiled at 96 °C, spun down for 1 min at 
1,000g and the assay was performed according to the manufacturer's protocol. The 
amount of ATP was determined from the standard curve and expressed as nM of ATP 
per mg of protein in the sample.  
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NADPH quantification 
NADPH concentration was determined using the NADP/NADPH Assay kit (Abcam, 
ab65349) according to the manufacturer’s protocol. Briefly, 4 × 106 macrophages 
were harvested in extraction buffer and filtered through a 10-kDa Spin column 
(Abcam, ab93349). The NADPH cycling reaction was performed for 2 h and NADPH 
amount was determined from the standard curve and normalized to protein 
concentration. 
 
Oxygen consumption rate and extracellular acidification rate 
Macrophages were plated in XF-96 cell culture plates (7.5 × 105 cells/well) and 
polarized to M1 and M2 in the presence or absence of 20 µM C75 for 16 h. 
Macrophages were then washed and incubated for 1 h in XF assay medium 
(unbuffered DMEM pH 7.4 with 10 mM glucose and 2 mM L-glutamine, with or 
without 2 mM sodium pyruvate) in a non-CO2 incubator at 37 °C as per 
manufacturer’s instructions (Seahorse Bioscience). Real time measurements of 
macrophage extracellular acidification rate (ECAR) and oxygen consumption rate 
(OCR) were performed using an XF-96 Extracellular Flux Analyzer (Seahorse 
Bioscience). Three or more consecutive measurements were obtained under basal 
conditions and after the sequential addition of 1 µM oligomycin, to inhibit 
mitochondrial ATP synthase; 1.5 µM FCCP (fluoro-carbonyl cyanide 
phenylhydrazone), a protonophore that uncouples ATP synthesis from oxygen 
consumption by the electron-transport chain; and 100 nM rotenone plus 1 µM 
antimycin A, which inhibits the electron transport chain. SRC is calculated as the 
difference between basal OCR and maximal OCR after the addition of FCCP. To 
assess glycolysis, three or more consecutive ECAR measurements were obtained 
under basal conditions and after the sequential addition of 1 µM oligomycin, to elicit 
maximal glycolytic capacity and 100 mM 2-DG (2-deoxyglucose) to inhibit 
glycolytic dependent ECAR. Measurement of endogenous and exogenous fatty acid 
oxidation (FAO) was performed according to manufacturer’s instructions (Seahorse 
Bioscience). In brief, macrophages were seeded and polarized toward M2 as above. 
After 16 h, macrophages were cultured in substrate limited DMEM medium 
containing 0.5 mM glucose, 1 mM GlutaMAX, 0.5 mM carnitine and 1% FBS for 24 
h. Macrophages were then washed and incubated for 1 h in FAO assay medium (111 
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mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM NaH2PO4) 
supplemented with 2.5 mM glucose, 0.5 mM carnitine, and 5 mM HEPES, pH 7.4 in 
the presence or absence of 40 µM etomoxir in a non-CO2 incubator at 37 °C. 1 mM 
palmitate conjugated to 0.17 mM BSA or BSA control was added to respective wells 
immediately prior to OCR measurement on XF-96 analyzer (Seahorse Bioscience). 
 
ROS measurement 
For mitochondrial and intracellular ROS measurements, macrophages were seeded at 
1 × 105 cells per well in a 96-well plate and polarized toward M1 and M2 as described 
above. Macrophages were then washed with warm PBS and incubated at 37°C with 5 
µM MitoSox (Invitrogen), mitochondrial superoxide indicator, or 10 µM CM-
H2DCFDA (Invitrogen), cytosolic ROS indicator, in serum-free phenol red-free RPMI 
1640 (Life Technologies) for 15 or 30 min respectively. Following washing, the 
fluorescence intensity of MitoSox and CM-H2DCFDA were measured on a ClarioStar 
plate reader at Excitation/Emission spectra of 510/580 nm or 495/520 nm 
respectively. Extracellular ROS kinetics was assessed using a horseradish peroxidase 
(HRP)-luminol-dependent chemiluminescence method. 2 × 106 cells per well were 
plated in a 6-well plate and polarized toward M1 and M2 and treated prior to assay 
with 20 µM C75, 100 µM etomoxir or 500 µM mitoTEMPO as indicated in the figure 
legends. Macrophages were harvested, washed in PBS then re-suspended in PBS 
(with added CaCl2 and MgCl2) using 5 × 105 cells per assay sample; for human 
macrophages 2.5 × 105 cells were used. 1 µM Luminol and 62.5 U/ml HRP were 
added to the cell suspension for 3 min and cells were then transferred to a white 96-
well luminometer plate (Berthold Technologies). 200 ng/ml PMA, 200 µg/ml serum-
opsonized zymosan or PBS control was added directly to each well and light emission 
recorded by a Berthold Centro LB 960 luminometer (Berthold Technologies). 
Experiments with murine and human neutrophils were similarly performed. 
 
In vitro infection assays 
Macrophages were infected with S. Typhimurium SL1344 for 45 min at MOI 10 in 
media containing 10% FCS or serum free media (Opti-MEM 1). Cells were then 
washed and maintained for a further 45 min with media containing 50 µg/ml 
gentamicin before replacing for media without antibiotics. After 2 h, cells were 
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washed with PBS and lysed with 0.1% Triton X-100 before plating serial dilutions in 
triplicate onto selective agar. For Mycobacterium bovis Bacillus Calmette Guérin 
(BCG) strain infection, macrophages were infected with BCG containing a luciferase 
reporter  for 0, 4, and 24 h30. Cells were then washed and lysed and relative light units 
(RLU), as direct correlates of colony forming units (c.f.u.), were measured as 
described30. 
 
In vitro macrophage cytokine stimulation assays 
1.5 × 105 macrophages per well were seeded in a 96-well plate. Cells were then 
washed and pre-treated with 20 µM C75, 100 µM etomoxir or vehicle only for 2 h 
and then stimulated with 200 µg/ml zymosan or 1 µg/ml of LPS. Supernatants were 
collected after 24 h and measured for IL-1b, IL-6, CXCL1 and TNF with ELISA 
according to manufacturer’s instruction (BD Bioscience).  
 
In vivo endotoxin administration 
E. coli LPS (2 mg/kg or 10 mg/kg) was injected intraperitoneally (i.p) into mice. All 
mice were male and aged between 5 and 8 weeks. At indicated time-points following 
i.p. LPS, serum was obtained by intracardiac puncture under terminal isoflurane 
anesthesia and mice were sacrificed. A graded scoring system, adapted from50, was 
employed to monitor the clinical severity of sepsis every 15 min following LPS 
injection, which consisted of scoring of respiration rate / breathing pattern (0-5), 
activity and movement (0-5) and appearance including changes to coat and eyes (0-5) 
conducted by two scientists independently. 
 
Immunoblot 
Cells were washed once in ice-cold PBS and lysed in RIPA buffer (50 mM Tris pH 
7.4, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS) with protease 
(Thermo Fisher Scientific, 78410) and phosphatase inhibitors (Thermo Fisher 
Scientific, 78426). Protein concentration was determined by BCA assay (Thermo 
Fisher Scientific, 23225) and equal amounts of proteins loaded onto SDS 
polyacrylamide gels. The proteins were transferred onto nitrocellulose membrane 
using a Trans-Blot Turbo transfer system (Bio-Rad). Membranes were incubated 
overnight with primary antibody, followed by corresponding secondary antibody and 
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the membranes were developed using 20X LumiGLO® Reagent (Cell Signaling, 
7003S). 
 
Immunoprecipitation (IP) 
Cells were washed three times with ice-cold PBS and then directly lysed with Tris-
Triton buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% 
Triton-X100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate) with added protease 
(Thermo Scientific, 78410) and phosphatase (Thermo Scientific, 78426) inhibitor 
cocktails. Lysed cells were centrifuged at 9,300g for 5 min at 4 °C to remove cell 
debris. Lysates were pre-cleared with either rabbit or mouse IgG bound to protein A 
sepharose beads (GE Healthcare, 17-5138-01) suspended in a 10% BSA-PBS solution 
rotated for 30 min at 4 °C. Pre-cleared lysates were added to protein A sepharose 
beads coated with a pull-down antibody (1:100) and rotated at 4 °C for 1 h. Beads 
were washed with lysis buffer and the bound proteins analyzed by immunoblot. 
 
Precipitation of IL-1b from supernatants 
Equal volumes of supernatants were precipitated using the TCA-DOC method. 
Briefly, 1/100 of 2% sodium deoxycholate was added to one volume of the 
supernatant, vortexed and left for 30 min at 4 °C. Next, 1/10 of trichloroacetic acid 
was added, samples vortexed and left overnight at 4° C. Samples were then spun 
down for 15 min at 4 °C at 15,000g. Pellets were washed once with one volume of ice 
cold acetone, air dried, resuspended in 2x loading buffer (4% SDS, 120 mM Tris HCl 
pH 6.8, 10% glycerol, 100 mM DTT and dash of bromphenol blue), boiled for 5 min 
and ran on the SDS-Page gel for further analysis.  
 
Silver stain 
Polyacrylamide gels were fixed for 1 h at 20 °C in 40% ethanol with 10% acetic acid. 
Gels were washed overnight with distilled water and then sensitized with 0.02% 
sodium thiosulphate for 1 min, washed and then stained for 20 min at 4 °C with 0.1% 
silver nitrate with 0.02% formaldehyde. Gels were developed with 3% sodium 
carbonate with 0.05% formaldehyde and staining terminated with 5% acetic acid for 5 
min. 
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Immunofluorescence staining 
Cells were seeded on glass coverslips and differentiated overnight as required. Cells 
were fixed with 4% paraformaldehyde containing either 0.2% or 1% Triton X-100 for 
15 min at 20 °C or 100% methanol at -20 °C for 15 min. Fixed cells were washed 
with PBS and non-specific binding blocked with either 5% normal serum or 0.5% 
milk before incubation with primary antibodies for 1 h at 20 °C. Unbound antibody 
was removed by washing with PBS and secondary antibody bound for 30 min at 20 
°C. Coverslips were then mounted with either Prolong or Mowiol mountant 
containing DAPI. Fluorescence was visualized with a Zeiss LSM 510 or a 
DeltaVision Spectris Deconvolution Microscope.  
 
Proximity-Ligation Assay 
Cells were fixed and stained with primary antibody as described above for 
immunofluorescence. Proximity-ligation assay (PLA) was performed as per 
manufacturer’s instructions (Duolink® In Situ, Olink Bioscience). In brief, unbound 
antibody was removed by washing twice for 5 min with 1x wash buffer A and PLA 
probes bound for 1 h at 37 °C. Unbound PLA probes were removed by washing twice 
for 5 min with 1x wash buffer A. Coverslips were incubated with Ligation-Ligase 
solution for 30 min at 37 °C. Ligation-Ligase solution was removed by washing twice 
for 2 min with 1x wash buffer A and coverslips were incubated with Amplification-
Polymerase solution for 100 min at 37 °C. Amplification-Polymerase solution was 
removed first by washing twice for 10 min with 1x wash buffer B and second by 
washing 1 min with 0.01% Wash buffer B. Coverslips were then mounted and 
fluorescence visualized as described in immunofluorescence staining. 
 
Oil Red O staining   
MΦ were seeded onto glass coverslips and allowed to differentiate overnight. Cells 
were washed twice with PBS and then incubated for 3 min in 100% propylene glycol 
(VWR) before staining with Oil Red O solution (0.5% Oil Red O [Amresco] in 
propylene glycol) for 10 min at 20 °C. Excess stain was removed by washing with 
85% propylene glycol and washing with distilled water. Cells were counterstained 
with hematoxylin and mounted with Kaiser’s glycerol gelatine (Merck Millipore). 
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Transmission electron microscopy 
Cells were fixed in 4% glutaraldehyde in 0.1M HEPES (pH 7.4) for 12 h at 4 °C, 
washed with 0.1M HEPES 5 times and then treated with 1% osmium ferricyanide at 
20 °C for 2 h. Cells were rinsed in water 5 times and treated with 2% uranyl acetate in 
0.05M maleate buffer (pH 5.5) for 2 h at 20 °C, rinsed and dehydrated in an 
ascending series of ethanol solutions (70% to 100%) and then treated with 2 changes 
of dry acetonitrile prior to infiltration with Quetol epoxy resin. Images were taken in 
an FEI Tecnai G2 operated at 120Kv using an AMT XR60B digital camera running 
Deben software. 
 
Quantitative real-time PCR 
Total RNA was isolated from cultured cells and tissues using RNeasy Mini Kit 
(QIAGEN) according to the manufacturer’s instructions. For RT-PCR, cDNA was 
synthesized using oligo(dT) primers and M-MLV reverse transcriptase followed by 
quantitative PCR analysis. The primers are shown in Supplementary Table 5.  
 
Statistical analysis 
Statistical significance was calculated as appropriate using unpaired, two-tailed 
Student’s t-test, Mann-Whitney U-test or ANOVA/Bonferroni as described in the 
figure legends. Data is represented as mean and standard error of the mean (S.E.M.). 
A P-value of <0.05 was considered significant. Data were analyzed with Graphpad 
Prism software (version 6).  
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Supplementary Figure 1 
Strep-tagged FAMIN expression in HEK293T cells 
Immunoblots (IB) of HEK293T lysates expressing N- and C-terminally Strep-tagged FAMIN.p254I and FAMIN.p254V variants for FAMIN and 
Strep-tag; b-actin loading control. Data are representative of three independent experiments. 
 
 
 
Supplementary Figure 2 
FAMIN localizes to peroxisomes 
(a) Co-localization by immunofluorescence (IF) of FAMIN (red) with PMP70 (green) in primary human macrophages (MF). DAPI nuclear staining, 
blue; scale bar = 10 µm. White box corresponds to enlarged images shown in Fig. 1d. (b–e) Co-localization by IF of FAMIN (red) with PMP70 
(green), catalase (green), cytochrome oxidase IV (green) and calreticulin (green) in THP-1 macrophages. DAPI, blue; scale bar = 10 µm for original 
images and 5 µm for enlarged images. Upper panels: original image, middle panels: enlargement of the area shown in the white box, lower panels: 
further enlargement as indicated. No significant co-localization of FAMIN was detected with CENP-A, centromere; caveolin-2, 
 
 
cholesterol/sphingolipid enriched plasma membrane; EEA1 and RAB5, early endosome; LAMP1, lysosomes; NUP98, nuclear envelope; fibrillin, 
nucleolus and syntaxin 6, trans-Golgi network (data not shown). (f) Proximity-ligation assay (PLA) of FAMIN in combination with PMP70, Catalase 
(red) or centromere protein A (red) as negative control in THP-1 macrophages. DAPI, blue; scale bar = 10 µm. White box corresponds to enlarged 
images shown in Fig. 1e. Data are representative of three independent experiments. 
 
 
 
 
 
Supplementary Figure 3 
Generation of mFamin–/–, mFaminp254I and mFaminp284R mice 
Schematic representation of the targeting strategy for creating a mFamin–/– allele in murine ES cells. The targeting vector, L1L2_Bact_P 
(International Mouse Knockout Consortium), contains a reading frame-independent LacZ gene trap cassette consisting of an En2 splice acceptor 
(SA), an internal ribosomal entry site (IRES), LacZ gene and a polyadenylation site (PA). The vector also contains a selectable marker consisting of a 
human b-actin promoter (hBactP), neomycin resistance gene (neo) and a PA site. The vector is flanked by flippase recognition target (FRT) sites to 
allow removal of the targeting cassette and conditional mFamin deletion upon Cre-mediated recombination of the loxP sites. mFaminp254I and 
mFaminp284R mice were generated by CRISPR/Cas9 genome editing to introduce nucleotide changes to encode p.254I or p.284R amino acids, 
respectively, at indicated positions. Nucleotides in mFamin exon 5 were targeted using guide RNAs, ‘line’ 7 and ‘line’ 9, respectively as outlined in 
the methods. Two different targeting oligodeoxynucleotides were used for each: one containing only the nucleotide changes leading to the amino 
acid substitutions, the other containing 2 additional synonymous nucleotide changes (‘wobble’) in the underlined region. 
 
 
 
Supplementary Figure 4 
Famin expression is highest in M1 macrophages and FAMIN deficiency does not affect FASN expression 
(a) mRNA expression of Famin in M0, M1 and M2 macrophages (MF). (b) mRNA expression of Fasn in M0, M1 and M2 macrophages. (c) 
Immunoblots (IB) of FASN in M1 and M2 macrophage cell lysates; b-actin loading control. Data are from one experiment with three mice 
representative of two (b,c; mean ± S.E.M.) or three independent experiments (c). 
 
 
 
 
 
Supplementary Figure 5 
FAMIN does not directly affect the Krebs cycle 
(a) Schematic representation of 1,2-13C-glucose incorporation, via citrate, into fatty acyl species. (b) Basal extracellular acidification rate (ECAR) of 
mFamin–/– and mFamin+/+ M1 and M2 macrophages (MF) in the presence of exogenous pyruvate (n = 5/14). (c) Relative levels of malate, fumarate, 
succinate and a-ketoglutarate in M1 and M2 macrophages. (d) Oxygen consumption rate (OCR) of mFamin–/– and mFamin+/+ M2 macrophages 
treated as indicated with 40 µM etomoxir (ETO) 1 h prior to OCR measurement and followed by sequential treatment (dotted vertical lines) with 
oligomycin (Oligo), FCCP, and rotenone plus antimycin (Rot + ant). *P < 0.05, **P < 0.01 (Unpaired, two-tailed Student’s t-test). Data are pooled 
from three independent experiments (b; mean ± S.E.M.), from one experiment with seven mice per group (c; mean ± S.E.M.) or from one experiment 
with three mice representative of two independent experiments (d; mean ± S.E.M.). 
 
 
 
Supplementary Figure 6 
 
 
FAMIN-deficient M2 macrophages exhibit impaired mitochondrial ROS- and FAO-dependent extracellular ROS production 
(a,b) Intracellular ROS measurement in unstimulated M1 and M2 mFamin–/– and mFamin+/+ macrophages (MF) stained with the cytosolic ROS 
indicator, 5-(and-6)-chloromethyl-2-7-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) and measured in relative fluorescence 
units, RFU. (c–i) Zymosan induced ROS production in M1 and M2 macrophages treated as indicated for 16 h with 20 µM C75; or 1 h 40 µM 
etomoxir (ETO) or 500 µM mitoTEMPO prior to stimulation; or silenced for Fasn (Fasn siRNA), Cpt1a (Cpt siRNA) or Cybb (Cybb siRNA) or 
scrambled siRNA (Ctrl siRNA); Left, ROS kinetic plots measured in relative light units, RLU and right, area under curve, AUC. (j) PMA-induced 
ROS production in mFamin–/– and mFamin+/+ neutrophils. (k) NADPH quantification in M1 and M2 macrophages cell lysates. *P < 0.05, **P < 0.01 
(Unpaired, two-tailed Student’s t-test). Data are from one experiment with three mice representative of two independent experiments (a–k; mean ± 
S.E.M.). 
 
 
 
 
Supplementary Figure 7 
FAMIN.pI254V and pC284R have impaired M2 macrophage ROS production 
(a) Zymosan-stimulated ROS production in mFamin–/–, mFaminp254V, mFaminp254I and mFaminp284R murine M2 macrophages (MF). (b) Zymosan 
induced ROS production in mFaminp254I and mFaminp254V M2 macrophages treated as indicated for 16 h with 20 µM C75. (c) Famin mRNA 
expression in M2 macrophages and neutrophils from healthy donors homozygous for the Crohn’s disease and leprosy risk (‘rs3764147G/G’) and non-
risk (‘rs3764147A/A’) haplotypes. Data are from one experiment with three mice representative of three independent experiments (a,b; mean ± 
S.E.M.) or pooled from ten independent experiments (c; mean ± S.E.M.). 	
